Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T99884
|
|||||
| Target Name |
HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
|
|||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Malaria [ICD-11: 1F40-1F45] | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Drugs in Phase 3 Trial | [+] 5 | + | ||||
| 1 | Hydroxychloroquine | Drug Info | Approved | Malaria | [2] | |
| 2 | Azithromycin + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [3] | |
| 3 | Darunavir + ritonavir + favipiravir + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [4] | |
| 4 | Darunavir + ritonavir + oseltamivir + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [4] | |
| 5 | Oseltamivir + hydroxychloroquine | Drug Info | Phase 3 | Coronavirus Disease 2019 (COVID-19) | [4] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 5 Inhibitor drugs | + | ||||
| 1 | Azithromycin + hydroxychloroquine | Drug Info | [1], [5] | |||
| 2 | Darunavir + ritonavir + favipiravir + hydroxychloroquine | Drug Info | [1], [5] | |||
| 3 | Darunavir + ritonavir + oseltamivir + hydroxychloroquine | Drug Info | [1], [5] | |||
| 4 | Hydroxychloroquine | Drug Info | [1], [5] | |||
| 5 | Oseltamivir + hydroxychloroquine | Drug Info | [1], [5] | |||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 3 | ClinicalTrials.gov (NCT04321278) Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT04303299) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial | |||||
| REF 5 | Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020 Mar 31. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.